Methods of treating or preventing neuropathic pain using sibutramine metabolites
US6710087B2 · kind B2 · utility
1Cited by
40References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 2002 |
| Grant date | Mar 23, 2004 |
| Priority date | — |
| Expiry date | Jun 4, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.